Sign in Subscribe
Cancer research

Breakthrough in Cancer Biomarker Detection: Nanopore-based ELISA Shows High Sensitivity

Strategic Insights

— 1 min read

Researchers from the Chinese People's Liberation Army (PLA) General Hospital have made a significant discovery in cancer diagnostics, developing an enzyme-linked immunosorbent assay (ELISA) that uses nanotechnology to detect cancer biomarkers with unprecedented sensitivity. This novel approach has the potential to revolutionize cancer diagnosis and point-of-care testing. According to the study, the nanopore-based ELISA demonstrated high sensitivity and multiplexing capability, allowing for the simultaneous detection of six biomarkers, including antigen and antibody biomarkers in blood samples.

Key Takeaways:

  • The researchers developed a nanopore-based ELISA that uses a-hemolysin-nanopore technology to detect cancer biomarkers.
  • The approach offers a low detection limit of up to 0.03 fg ml, enabling precise biomarker quantification.
  • The nanopore-based ELISA can simultaneously detect six biomarkers, including antigen and antibody biomarkers in blood samples.
  • This technology has the potential to revolutionize cancer diagnosis and point-of-care testing.
  • The study demonstrates high sensitivity and multiplexing capability, making it suitable for next-generation diagnostic applications.
  • The research was conducted by Peng Song, Yakun Yi, Ziyi Li, Jinzhou Ju, Guixiang Sun, Qianyuan Ren, Ke Zhou, Lei Liu, and Hai-Chen Wu from the Chinese People's Liberation Army (PLA) General Hospital.

Statistics:

  • Detection limit: up to 0.03 fg ml
  • Number of biomarkers detected: six (including antigen and antibody biomarkers)
  • Sensitivity: high sensitivity demonstrated by the nanopore-based ELISA
  • Multiplexing capability: simultaneous detection of six biomarkers
  • Potential impact: revolutionizing cancer diagnosis and point-of-care testing

Sources:

  • Song, P. et al. (2025). Nanopore-based enzyme-linked immunosorbent assay for cancer biomarker detection. Nature Nanotechnology.
  • Nature Portfolio. (2025). Heidelberger Platz 3, Berlin, 14197, Germany. (Contact information)
  • NewsRx. (2025). Chinese People's Liberation Army (PLA) General Hospital Reports Findings in Cancer Biomarkers (Nanopore-based enzyme-linked immunosorbent assay for cancer biomarker detection). Chemicals & Chemistry, p 374.

Read more